Novel pharmacotherapy of acute hereditary angioedema with bradykinin B<sub>2</sub>‐receptor antagonist icatibant

M, Bas; Bier, H.; Greve, Jens; Kojda, Georg; Hoffmann, Thomas

doi:10.1111/j.1398-9995.2006.01197.x

Cited by 40 publications

(26 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a phase II trial for the treatment of eight patients with acute attacks in HAE, icatibant appeared effective and well tolerated [44]. One recent case study demonstrated that subcutaneous icatibant could induce rapid onset of symptom relief, even as compared to C1-INH replacement therapy [45]. Icatibant is in phase III trials [10].…”

Section: Icatibantmentioning

confidence: 98%

C1-inhibitor deficiencies (hereditary angioedema): Where are we with therapies?

Lock¹,

Gompels

2007

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Hereditary angioedema, an autosomal dominant disorder, presents clinically as recurrent episodes of swelling. It results from either deficient production or function of C1 inhibitor. Acquired angioedema is associated with lymphoproliferative or autoimmune disease. Conventionally attenuated androgens and antifibrinolytics have been used for prophylaxis, both for the long term and presurgically. Fresh frozen plasma and plasma-derived C1 inhibitor concentrate have been used primarily for treatment of acute attacks. All have drawbacks in side effects or potential for infection transmission. New treatments (recombinant C1 inhibitor, icatibant, DX-88, and for acquired angioedema, rituximab) so far show good safety profiles. Early data suggest these may be effective treatment alternatives. The efficacy of current treatment and the potential held by newer agents that target specific elements in complement or kinin pathways are examined. Some agents are likely to have a wider role in treatment of other, more common, forms of angioedema.

show abstract

Section: Icatibantmentioning

confidence: 98%

C1-inhibitor deficiencies (hereditary angioedema): Where are we with therapies?

Lock¹,

Gompels

2007

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…[2] Bradykinin is a very potent vasodilator and plays a pivotal role in the development of angioedema. [9] Bradykinin acts through the bradykinin receptor 2 (B2) present on vascular endothelial cell membrane resulting in vasodilatation and increased vascular permeability.…”

Section: Molecular Pathologymentioning

confidence: 99%

Hereditary angioedema: An update

Nigam¹

2011

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

“…Icatibant is a bradykinin type 2 receptor antagonist. 43 The bradykinin type 2 receptor is a member of the 7-transmembrane-spanning receptor superfamily. This 10-amino acid synthetic peptide is not inhibitory for the bradykinin I receptor, which optimally recognizes des-Arg-bradykinin.…”

Section: Kinin Pathway Inhibitionmentioning

confidence: 99%